

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>INT'L FILING NO.</b>		10/596,503	
				<b>INT'L FILING DATE</b>		6/15/06	
				<b>APPLICANT</b>		Bailey et al.	
				<b>GROUP</b>		1624	
				<b>EXAMINER</b>		Coleman	
				<b>ATTORNEY DOCKET NO.</b>		PB60626USw	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
/B.C./	1.	4,210,749	7/1/1980	Shetty	540	594	
/B.C./	2.	5,364,791	11/15/1994	Vegeto et al.	435	320.1	
/B.C./	3.	5,874,534	2/23/1999	Vegeto et al.	530	350	
/B.C./	4.	5,935,934	10/10/1999	Vegeto et al.	514	44	
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>
/B.C./	5.	WO 96/05194	2/2/1996	PCT			abstract only
** /B.C./	6.	WO 00/23437	4/27/2000	PCT			abstract only
** /B.C./	7.	WO 02/02530	1/10/2002	PCT			abstract only
/B.C./	8.	WO 01/03680	1/18/2001	PCT			
** /B.C./	9.	WO 01/87834	11/22/2001	PCT			
** /B.C./	10.	WO 02/14513	2/21/2002	PCT			abstract only
/B.C./	11.	WO 00/21951	4/20/2000	PCT			
** /B.C./	12.	WO 02/15934	2/28/2002	PCT			abstract only
** /B.C./	13.	WO 02/46186	6/13/2002	PCT			abstract only
/B.C./	14.	WO 03/68751	8/21/2003	PCT			
/B.C./	15.	WO 03/68752	8/21/2003	PCT			
/B.C./	16.	WO 03/95428	11/20/2003	PCT			
/B.C./	17.	WO 04/56369	7/8/2004	PCT			
/B.C./	18.	1 331 010	7/30/2003	EP			
** /B.C./	19.	2207430	7/23/1981	DE			abstract only
** /B.C./	20.	2171879	9/28/1973	FR			abstract only
/B.C./	21.	1 268 243	3/22/1972	GB			
** /B.C./	22.	2001226269	8/21/2001	JP			abstract only
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
/B.C./	23.	GIOVANNINI et al., "Effects of histamine H <sub>3</sub> receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia," <i>Behavioral Brain Res.</i> <b>104</b> :147-155 (1999).					
/B.C./	24.	LEURS et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists," <i>TIPS</i> <b>19</b> :177-183 (May 1998).					
/B.C./	25.	LOVENBERG et al., "Cloning and Functional Expression of the Human Histamine H <sub>3</sub> Receptor," <i>Molecular Pharmacology</i> <b>55</b> :1101-1107 (1999).					
/B.C./	26.	ONODERA and WATANABE, "Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).					
/B.C./	27.	SCHLICKER et al., "Modulation of neurotransmitter release via histamine H <sub>3</sub> heteroreceptors," <i>Fundam Clin Pharmacol</i> <b>8</b> :128-137 (1994).					
/B.C./	28.	STARK, Recent advances in histamine H <sub>3</sub> /H <sub>4</sub> receptor ligands, <i>Expert Opinion on Therapeutic Patents</i> <b>13</b> (6):851-865 (2003).					
EXAMINER					DATE CONSIDERED		
/Brenda Coleman/					09/05/2008		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

\*\* Structures only